Publications by authors named "Keith Fay"

Claim this Profile
L
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, Stephen J Schuster, Sarit E Assouline, Keith Fay

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
Elise A Chong, Elicia Penuel, Ellen B Napier, Rachel K Lundberg, Lihua E Budde, Keith Fay

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIP1L1::PDGFRA fusion driving three synchronous haematological malignancies.
Michael Krigstein, Anna Menzies, Keith Fay, Robyn Lukeis, Karen Cheung

Pathology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysis.
Richard Blennerhassett, Jad Othman, Amber Biscoe, David Kliman, Georgia Mills, Keith Fay

Intern Med J· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, Stephen J Schuster, Chan Y Cheah, Keith Fay

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
Xavier Brennan, Barbara Withers, Andrew Jabbour, Sam Milliken, Eugene Kotlyar, Keith Fay

Intern Med J· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Lihua E Budde, Laurie H Sehn, Matthew Matasar, Stephen J Schuster, Sarit Assouline, Keith Fay

Lancet Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome.
Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Keith Fay

EJHaem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
Julian Lindsay, Jad Othman, Yvonne Kong, Annie Yip, Sebastiaan Van Hal, Keith Fay

Open Forum Infect Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
Julian Lindsay, Jad Othman, Michelle K Yong, David Ritchie, Lynette Chee, Keith Fay

Transpl Infect Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
Julian Lindsay, Jad Othman, Ian Kerridge, Keith Fay, William Stevenson

Transpl Infect Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
Morton Coleman, David Belada, René-Olivier Casasnovas, Rémy Gressin, Hui-Peng Lee, Keith Fay

Leuk Lymphoma· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG.
Jad Othman, Matthew Greenwood, John Moore, Stephen Larsen, Anne-Marie Watson, Keith Fay

Biol Blood Marrow Transplant· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma.
Jad Othman, Tasman Armytage, Kelly Wong, Christopher Arthur, Keith Fay

Bone Marrow Transplant· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival.
Christopher Arthur, Anthony Jeffrey, Eva Yip, Vicki Katsioulas, Anastasios Nalpantidis, Keith Fay

Leuk Lymphoma· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis.
Chun Kei Kris Ma, Irene García-Cadenas, María Laura Fox, Sylvia Ai, Ian Nivison-Smith, Keith Fay

Bone Marrow Transplant· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency.
Elissa K Deenick, Adrienne Morey, Mark Danta, Louise Emmett, Keith Fay

J Clin Immunol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation.
Julian Lindsay, Indy Sandaradura, Kelly Wong, Chris Arthur, William Stevenson, Keith Fay

J Antimicrob Chemother· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Keith Fay

Haematologica· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Gayathri Kumarasinghe, Orly Lavee, Andrew Parker, Ian Nivison-Smith, Samuel Milliken, Keith Fay

J Heart Lung Transplant· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.
Joerg P Halter, W Michael, M Schüpbach, Hanna Mandel, Carlo Casali, Keith Fay

Brain· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
Grace Gifford, Kelly Wong, Ian Kerridge, William Stevenson, Chris Arthur, Keith Fay

Am J Hematol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute life-threatening cardiovascular toxicity with umbilical cord blood infusion: the role of dextran.
Robert W Ma, John M Kwan, David D Ma, Keith C Fay

Am J Hematol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Timothy P Hughes, Susan Branford, Deborah L White, John Reynolds, Rachel Koelmeyer, Keith Fay

Blood· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extramedullary presentation of acute leukaemia: a case of myeloid/natural killer cell precursor leukaemia.
Vivien M Y Chen, Kirsten McIlroy, Jenny P Y Loui, Keith Fay, Christopher Ward

Pathology· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis